XDx, Inc. Announces Highmark’s Coverage of AlloMap® for Monitoring Heart Transplant Rejection

Published: Nov 08, 2011

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap® for its beneficiaries. Highmark considers AlloMap “medically necessary” for monitoring heart transplant rejection, recognizing the clinical benefits of a non-invasive method for managing rejection in stable heart transplant recipients. AlloMap now is covered for approximately two-thirds of the United States heart transplant population.

Back to news